NCT02455960

Protective Effects of Oral L-Arginine CI-AKI

Protective Effects of Oral L-Arginine Supplement in Patients With CKD After Intravenous Contrast Media Injection

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 112 (estimated)
• Sponsor: Phramongkutklao College of Medicine and Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This trial was performed to examine the efficacy of oral L-arginine for preventing CI-AKI in chronic kidney disease (CKD) patients.

Detailed description

Contrast-induced acute kidney injury (CI-AKI) is a common complication in hospitalized patients. Nitric oxide-signal transduction plays an important role in prevention of CI-AKI. L-Arginine is an amino acid involved in ammonia detoxification, and is well known as a precursor to nitric oxide, a key component of endothelial-derived relaxing factor. This is a prospective randomized, double blind, placebo controlled trial among CKD stage 3-4 patients undergoing computer tomography. Eligible patients were randomly assigned to two groups: (1) arginine 3 g/day or 6 capsules per day, and (2) placebo 6 capsules per day for 3 days before contrast media injection. Serum cystatin C, serum creatinine and estimated GFR was measured at baseline and 48 hours after procedure.

Conditions

• Contrast Induced AKI

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	L-arginine	Comparison of the efficacy of L-arginine 3 grams for days versus placebo in contrast induced AKI prevention
DIETARY_SUPPLEMENT	Placebo

Timeline

• Start date: 2014-09-01
• Primary completion: 2016-04-01
• Completion: 2016-05-01
• First posted: 2015-05-28
• Last updated: 2015-05-28

Locations

1 site across 1 country: Thailand